3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Myeloid
1
Classical hematology
1
Conditions
Venous Thromboembolism
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Hemorrhage
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
550
Specimen Handling
462
Carboplatin
441
Magnetic Resonance Spectroscopy
429
Cyclophosphamide
412
Cisplatin
398
Radiotherapy
313
Gemcitabine
310
Bevacizumab
306
Paclitaxel
294
Biopsy
259
Drug Therapy
248
Capecitabine
241
Oxaliplatin
239
fludarabine
238
Nivolumab
224
venetoclax
219
Injections
213
Docetaxel
205
Fluorouracil
202
Dexamethasone
186
Radiosurgery
172
Rituximab
158
Pemetrexed
153
Standard of Care
145
durvalumab
143
Leucovorin
138
atezolizumab
137
toripalimab
134
tislelizumab
134
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Interventional
×
N(4)-oleylcytosine arabinoside
×
Clear all
NCT05498428
2026-05-08
PALOMA-2
Janssen Research & Development, LLC
Phase 2
Recruiting
520 enrolled
NCT05198960
2026-03-20
AVAJAK
University Hospital, Brest
Phase 3
Recruiting
1,308 enrolled